


**Product Name** : CKD-519  
**Cat. No.** : PC-35463  
**CAS No.** : 1402796-27-3  
**Molecular Formula** : C<sub>31</sub>H<sub>34</sub>F<sub>7</sub>NO<sub>3</sub>  
**Molecular Weight** : 601.606  
**Target** : CETP  
**Solubility** : 10 mM in DMSO



## Biological Activity

CKD-519 (Rocacetrapiib, CKD519) is a potent, selective **cholesteryl ester transfer protein (CETP)** inhibitor, inhibits the CETP-mediated transfer of cholesteryl ester in human serum with IC<sub>50</sub> of 2.3 nM.

CKD-519 (Rocacetrapiib) exhibits a maximum of 70%-86% inhibition of CETP activity and 25%-48% increase of HDL-C levels after two weeks of oral administration of 1, 3, or 10 mg/kg in transgenic mice expressing human CETP/apolipoprotein AI.

CKD-519 (Rocacetrapiib, CKD519) is being developed for the treatment of dyslipidemia to raise high-density lipoprotein cholesterol.

## References

Kim CO, et al. *Drug Des Devel Ther.* 2016 Nov 15;10:3763-3770. eCollection 2016.

Lee S. Abstract 11228: a novel and potent CETP inhibitor, CKD-519 exerts strong HDL increment and anti-atherosclerotic effects. *Circulation.* 2013;128(Suppl 22):A11228.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com